Priveterra Acquisition Reports Authorization To List On NYSE Upon Completion Of Business Combination With AEON Biopharma
Portfolio Pulse from Benzinga Newsdesk
Priveterra Acquisition has been authorized to list on the NYSE following its business combination with AEON Biopharma. Post-merger, AEON will be a wholly owned subsidiary of Priveterra, which will change its name to AEON Biopharma, Inc. Trading under the new ticker symbol 'AEON' is expected to begin on July 24, 2023.
July 17, 2023 | 9:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AEON Biopharma will be listed on the NYSE under the ticker 'AEON' following its merger with Priveterra Acquisition. Trading is expected to start on July 24, 2023.
The news of the merger and subsequent listing on the NYSE is likely to generate investor interest in AEON Biopharma. This could potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100